Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03939026 · ClinicalTrials.gov registry record · Phase 1
Safety and Efficacy of ALLO-501 Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell or Follicular Lymphoma
A Phase 1 study, sponsored by Allogene Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 50
- Enrollment target
NCT03939026 is a Phase 1 study that has completed, run by Allogene Therapeutics. The registered enrollment target is 50 participants.
The verdict
NCT03939026, a Phase 1 study, has completed, sponsored by Allogene Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 50 participants
- Enrollment target
Study Summary
The purpose of the ALPHA study is to assess the safety, efficacy, cell kinetics and immunogenicity of ALLO-501 in adults with relapsed or refractory large B-cell lymphoma or follicular lymphoma after a lymphodepletion regimen comprising fludarabine, cyclophosphamide, and ALLO-647.
Interventions
- DRUG Cyclophosphamide
- DRUG Fludarabine
- BIOLOGICAL ALLO-647
- GENETIC ALLO-501
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2019-05-01 |
| Est. Completion | 2025-01-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03939026
The ClinicalTrials.gov registry entry for NCT03939026 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allogene Therapeutics, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Cyclophosphamide is the first listed.
NCT03939026 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03939026 about?
NCT03939026 is a clinical study titled "Safety and Efficacy of ALLO-501 Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell or Follicular Lymphoma". The purpose of the ALPHA study is to assess the safety, efficacy, cell kinetics and immunogenicity of ALLO-501 in adults with relapsed or refractory large B-cell lymphoma or follicular lymphoma after a lymphodepletion regimen comprising fludarabine, cyclophosphamide, and ALLO-647.
What is the current status of trial NCT03939026?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2019-05-01. Estimated completion is 2025-01-28.
What interventions are being tested in trial NCT03939026?
The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), ALLO-647 (BIOLOGICAL), ALLO-501 (GENETIC).
Who is sponsoring clinical trial NCT03939026?
This trial is sponsored by Allogene Therapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.